INVO BIOSCIENCE INC (INVO) Fundamental Analysis & Valuation

NASDAQ:INVO • US44984F4019

Current stock price

0.833 USD
-0.03 (-2.91%)
At close:
0.825 USD
-0.01 (-0.96%)
After Hours:

This INVO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. INVO Profitability Analysis

1.1 Basic Checks

  • In the past year INVO has reported negative net income.
  • In the past year INVO has reported a negative cash flow from operations.
  • INVO had negative earnings in each of the past 5 years.
  • INVO had negative operating cash flow in 4 of the past 5 years.
INVO Yearly Net Income VS EBIT VS OCF VS FCFINVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -2M -4M -6M -8M -10M

1.2 Ratios

  • INVO has a worse Return On Assets (-39.30%) than 61.70% of its industry peers.
  • Looking at the Return On Equity, with a value of -519.72%, INVO is doing worse than 88.30% of the companies in the same industry.
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROIC N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INVO Yearly ROA, ROE, ROICINVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 500 -500 1K

1.3 Margins

  • With a Gross Margin value of 44.86%, INVO is not doing good in the industry: 62.23% of the companies in the same industry are doing better.
  • In the last couple of years the Gross Margin of INVO has declined.
  • INVO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 44.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
INVO Yearly Profit, Operating, Gross MarginsINVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. INVO Health Analysis

2.1 Basic Checks

  • INVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, INVO has more shares outstanding
  • Compared to 1 year ago, INVO has an improved debt to assets ratio.
INVO Yearly Shares OutstandingINVO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M 2M
INVO Yearly Total Debt VS Total AssetsINVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M

2.2 Solvency

  • INVO has an Altman-Z score of -5.70. This is a bad value and indicates that INVO is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -5.70, INVO is not doing good in the industry: 70.74% of the companies in the same industry are doing better.
  • INVO has a Debt/Equity ratio of 1.51. This is a high value indicating a heavy dependency on external financing.
  • INVO's Debt to Equity ratio of 1.51 is on the low side compared to the rest of the industry. INVO is outperformed by 82.45% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Altman-Z -5.7
ROIC/WACCN/A
WACC7.27%
INVO Yearly LT Debt VS Equity VS FCFINVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M 6M -6M

2.3 Liquidity

  • A Current Ratio of 0.30 indicates that INVO may have some problems paying its short term obligations.
  • INVO has a Current ratio of 0.30. This is amonst the worse of the industry: INVO underperforms 94.68% of its industry peers.
  • INVO has a Quick Ratio of 0.30. This is a bad value and indicates that INVO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • INVO has a worse Quick ratio (0.27) than 95.21% of its industry peers.
Industry RankSector Rank
Current Ratio 0.3
Quick Ratio 0.27
INVO Yearly Current Assets VS Current LiabilitesINVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. INVO Growth Analysis

3.1 Past

  • INVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 79.65%, which is quite impressive.
  • Looking at the last year, INVO shows a very strong growth in Revenue. The Revenue has grown by 384.42%.
  • The Revenue has been growing by 43.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%

3.2 Future

  • The Earnings Per Share is expected to grow by 41.42% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, INVO will show a very strong growth in Revenue. The Revenue will grow by 101.26% on average per year.
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INVO Yearly Revenue VS EstimatesINVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 50M 100M 150M
INVO Yearly EPS VS EstimatesINVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

1

4. INVO Valuation Analysis

4.1 Price/Earnings Ratio

  • INVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INVO Price Earnings VS Forward Price EarningsINVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INVO Per share dataINVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INVO's earnings are expected to grow with 41.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INVO Dividend Analysis

5.1 Amount

  • INVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

INVO Fundamentals: All Metrics, Ratios and Statistics

INVO BIOSCIENCE INC

NASDAQ:INVO (10/21/2024, 8:21:24 PM)

After market: 0.825 -0.01 (-0.96%)

0.833

-0.03 (-2.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12
Earnings (Next)11-11
Inst Owners7.01%
Inst Owner Change0%
Ins Owners9.11%
Ins Owner Change0%
Market Cap3.26M
Revenue(TTM)5.76M
Net Income(TTM)-7.09M
Analysts43.33
Price Target20.4 (2348.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.57
P/FCF N/A
P/OCF N/A
P/B 2.39
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.24
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-1.02
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS1.47
BVpS0.35
TBVpS-2.1
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -39.3%
ROE -519.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 44.86%
FCFM N/A
ROA(3y)-122.53%
ROA(5y)-112.88%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-26.71%
GM growth 5Y-15.12%
F-Score4
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 1.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.84%
Cap/Sales 5.02%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.3
Quick Ratio 0.27
Altman-Z -5.7
F-Score4
WACC7.27%
ROIC/WACCN/A
Cap/Depr(3y)577.96%
Cap/Depr(5y)746.78%
Cap/Sales(3y)8.92%
Cap/Sales(5y)8.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%79.67%
EPS Next Y50%
EPS Next 2Y41.42%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)384.42%
Revenue growth 3Y42.68%
Revenue growth 5Y43.87%
Sales Q2Q%473.94%
Revenue Next Year199.65%
Revenue Next 2Y172.81%
Revenue Next 3Y152.43%
Revenue Next 5Y101.26%
EBIT growth 1Y45.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y46.99%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.93%
OCF growth 3YN/A
OCF growth 5YN/A

INVO BIOSCIENCE INC / INVO Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INVO BIOSCIENCE INC?

ChartMill assigns a fundamental rating of 2 / 10 to INVO.


What is the valuation status of INVO BIOSCIENCE INC (INVO) stock?

ChartMill assigns a valuation rating of 1 / 10 to INVO BIOSCIENCE INC (INVO). This can be considered as Overvalued.


What is the profitability of INVO stock?

INVO BIOSCIENCE INC (INVO) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for INVO stock?

The Earnings per Share (EPS) of INVO BIOSCIENCE INC (INVO) is expected to grow by 50% in the next year.